Table 7.

Effect of duration of treatment with aspirin on the risk of UGIB and perforation among current users as compared to non-use by aspirin dose

	All cases	Controls	Adjusted RR*
	(N=2,105)	(N=11,500)	(95%CI)
Daily dose as instructed/
Days of treatment/
75 mg
1-60	17	32	3.2 (1.7-6.1)
61-180	20	37	2.9 (1.6-5.2)
181-730	53	166	1.7 (1.2-2.5)
>731	51	185	1.7 (1.3-4.6)
150 mg
1-60	13	11	6.6 (2.7-15.9)
61-180	11	23	2.7 (1.2-6.0)
181-730	26	83	2.0 (1.2-3.2)
>730	34	128	1.5 (1.0-2.2)
300 + mg
1-60	10	9	6.0 (2.2-16.2)
61-180	3	11	1.9 (0.5-7.1)
181-730	17	37	2.6 (1.4-4.9)
>730	32	115	1.7 (1.1-2.6)

^*Adjusted for sex, age, calendar year, antecedents of gastrointestinal disorders, smoking status, alcohol consumption and use of NSAIDs, anticoagulants, steroids, SSRIs and paracetamol.